Navigation Links
Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
Date:3/12/2010

certain other products; our ability to successfully implement our acquisition and in-licensing strategy; regulatory or other limits on the availability of controlled substances that constitute the active ingredients of some of our products and products in development; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by third parties or the government, and the performance of indemnitors with respect to claims for which we have been indemnified; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total revenues; a determination by a regulatory agency that we are engaging or have engaged in inappropriate sales or marketing activities, including promoting the "off-label" use of our products and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2009, which was filed with the Securities and Exchange Commission on February 26, 2010. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... the Morgan Stanley Healthcare conference on Tuesday, September ... Huennekens , president and chief executive officer, will ...
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... corporate and clinical activities at the company ... ongoing clinical trials and future clinical development ... Executive Officer Robert Hershberg , M.D., ...
(Date:9/2/2014)... Sept. 2, 2014  VentiRx Pharmaceuticals, Inc., ... the development and commercialization of novel Toll-like ... the U.S. Food and Drug Administration (FDA) ... investigation of motolimod (VTX-2337) when administered in ... the treatment of women with ovarian cancer ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... May 20, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) ... intermediates, and contract research and manufacturing services to customers ... the 2011 fiscal year (FY) ended March 31, 2011. ... in fiscal year 2011, Neuland delivered on our commitment ...
... Winner Medical Group Inc. (Nasdaq: WWIN ; ... medical dressings, medical disposables and non-woven fabric made from ... that its PurCotton Industrial Wipes was nominated one of ... Award™. The Company will compete with the ...
Cached Medicine Technology:Neuland Labs Reports Financial Results for Fiscal Year 2011 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 3Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 4
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
(Date:9/2/2014)... Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery ... the foundation of all natural Moroccan plant extracts to ... There is nothing similar to Vitality Hair Recovery cream ... is a commonly encountered problem for men and women ... been limited to existing medications offering mediocre results, considerable ...
(Date:9/2/2014)... September 02, 2014 Humility of Mary Health ... 18 at St. Elizabeth Health Center, 1044 Belmont Ave. , ... about more than 200 common health problems as well as ... and injury, and advice on when to seek medical attention. ... noon in the Youngstown Room; the evening session runs from ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 Researchers in ... woman who developed mesothelioma after being exposed to asbestos-contaminated work ... has all the details of the report in a new ... Doctors at the ESI Model Hospital say their patient was ... and breathlessness. Further investigation found that she had come in ...
Breaking Medicine News(10 mins):Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2
... , NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... develops novel therapeutic proteins that disrupt the advance of ... in the process of acquiring three promising new drug ... in royalty fees in the mid to long term. ...
... , , , ... to those who are here illegally," President Obama said in a carefully ... last night. The problem, notes the Federation for American Immigration Reform (FAIR), ... Health Care Act of 2009, clearly would benefit illegal aliens. , ...
... , , SAN FRANCISCO, ... professional association in U.S. history took a major step forward ... Nurses Association/National Nurses Organization in San Francisco voted unanimously to ... National Nurses United, unifying the 86,000-member CNA/NNOC with the ...
... (GSA) invites all journalists to attend its 62nd Annual ... the field of aging from November 18 to 22 ... An estimated 3,500 professionals are expected to attend the ... Atlanta Marriott Marquis . The theme for 2009 is "Creative ...
... The University of Miami School of Nursing and Health Studies ... Foundation in the amount of $30,000 to support six students ... program. "Family nurse practitioners have a promising future" said Nilda ... Studies. "The Dr. John T. Macdonald Foundation grant will help ...
... , , LAKE FOREST, Ill., ... leading global specialty pharmaceutical and medication delivery company, today announced that ... on Thursday, Sept. 17, 2009. The company,s senior leadership team and ... , A streaming audio webcast of the event, ...
Cached Medicine News:Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 2Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 3Health News:President Obama Misleads Public on Health Care for Illegal Aliens; Illegal Aliens Would Benefit Under H.R. 3200 2Health News:California Nurses/NNOC, Nation's Largest Nurses' Organization, Unanimously Endorses Joining RN Super Union 2Health News:An invitation to the nation's premier aging conference 2Health News:UM receives grant to support graduate students in the family nurse practitioner program 2Health News:Hospira to Host 2009 Investor Day 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: